AbbVie

The U.S. health agency extended the review period for the expanded use of AbbVie Inc.’s psoriasis drug Skyrizi by three months, citing the need for more time to review additional data submitted by the company.

The U.S. Food and Drug Administration was reviewing the application for the use of Skyrizi in patients aged 16 years of age or older with moderate to severe Crohn’s disease, a type of inflammatory bowel disease.

Teva

Teva Pharmaceutical Industries Ltd. reported solid results for full-year 2021, posting $15.9 billion in revenue including a gain of $4.1 billion from the fourth quarter. The company recently settled an opioid-related case in Texas and is preparing to pay as much as $3.6 billion in cash and medicine to settle the lawsuits filed against Teva.

The U.S. Food and Drug Administration approved Sanofi’s proposed drug to address red blood cell destruction in patients living with a rare form of anemia called cold agglutinin disease (CAD). 

The U.S. Food and Drug Administration approved Azurity Pharmaceuticals Inc.’s Fleqsuvy (baclofen oral suspension), 25 mg per 5 mL (5 mg/mL), Concentrated Formulation for the treatment of spasticity from multiple sclerosis or patients with spinal cord injuries and other spinal cord diseases.

AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.

Takeda

With two assets licensed from Takeda, Oak Hill Bio launched with a focus on developing therapeutics for patients and extremely preterm infants who are suffering from rare autoimmune diseases.

Biogen

The European Commission (EC) granted marketing authorization for Biogen Inc.’s Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).

During 2021, Snow Companies looks back at 20 years of the patient engagement agency’s history. Over these years, Snow has worked with large numbers of patients and captured their stories. The agency is highlighting 20 of these stories at 20patients.com over the next few weeks.

BrainStorm Cell Therapeutics announced positive data from a Phase II safety and efficacy study of NurOwn in progressive multiple sclerosis on Oct. 14.

Roche’s Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Oct. 13